NCT01564784 2019-01-09
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 3 Completed
Pfizer
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC